ストックスクリーナーアプリを入手
32.98
1.14%
0.375
前日終値:
$32.60
開ける：
$32.56
24時間の取引高:
1.22M
Relative Volume:
0.53
時価総額：
$4.12B
収益：
$1.24B
当期純損益:
$209.00M
株価収益率:
19.86
EPS:
1.6605
ネットキャッシュフロー:
$-94.86M
1週間 パフォーマンス:
+6.81%
1か月 パフォーマンス:
-1.46%
6か月 パフォーマンス:
+35.19%
1年 パフォーマンス:
+246.35%
1日の値動き範囲:
$30.87
$33.44
1週間の範囲:
$30.33
$33.44
52週間の値動き範囲:
$8.64
$38.00
Indivior Pharmaceuticals Inc Stock (INDV) Company Profile
名前
Indivior Pharmaceuticals Inc
セクター
電話
804-379-1090
住所
10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD
Compare INDV vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INDV
Indivior Pharmaceuticals Inc
|
32.98 | 4.08B | 1.24B | 209.00M | -94.86M | 1.6605 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.25 | 57.09B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
122.38 | 51.65B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.20 | 45.70B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.56 | 36.69B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
544.97 | 23.19B | 3.13B | 1.27B | 1.12B | 26.39 |
Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-06 | 開始されました | H.C. Wainwright | Buy |
| 2025-07-22 | 再開されました | Jefferies | Buy |
| 2025-01-28 | 開始されました | Rodman & Renshaw | Buy |
| 2024-07-23 | 開始されました | Piper Sandler | Overweight |
| 2024-04-03 | 開始されました | Craig Hallum | Buy |
| 2023-07-13 | 開始されました | Northland Capital | Outperform |
すべてを表示
Indivior Pharmaceuticals Inc (INDV) 最新ニュース
Implied Volatility Spikes for Indivior Pharmaceuticals Equity Options - Bitget
Implied Volatility Surging for Indivior Pharmaceuticals Stock Options - Yahoo Finance
Indivior (INDV) Q4 2025 Earnings Call Transcript - AOL.com
Is It Time To Reassess Indivior Pharmaceuticals (INDV) After Its Recent Pullback In Price? - simplywall.st
Global Transdermal Skin Patch Market Size, Growth, Trends & - openPR.com
Royce & Associates LP Buys Shares of 246,524 Indivior PLC $INDV - MarketBeat
Indivior PLC (NASDAQ:INDV) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Indivior Pharmaceuticals, Inc. (INDV): Investor Outlook With 45% Potential Upside - DirectorsTalk Interviews
Quantbot Technologies LP Makes New Investment in Indivior PLC $INDV - MarketBeat
Equities Analysts Issue Forecasts for Indivior Q4 Earnings - MarketBeat
Indivior Pharmaceuticals (INDV) Valuation Check After Strong Long Term Shareholder Returns - Sahm
Indivior’s Strong 2025 Results and US$400 Million Buyback Might Change The Case For Investing In Indivior Pharmaceuticals (INDV) - simplywall.st
Decoding Indivior Pharmaceuticals Inc (INDV): A Strategic SWOT I - GuruFocus
A Look At Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Its Recent Name Change - Yahoo Finance
Indivior Pharmaceuticals, Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Indivior (NASDAQ:INDV) Announces Earnings Results - MarketBeat
INDVIndivior Pharmaceuticals Inc. Latest Stock News & Market Updates - Stock Titan
Indivior Pharmaceuticals Inc. (INDV) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance
Sector Update: Health Care - marketscreener.com
Earnings call transcript: Indivior Q4 2025 beats expectations, stock rises - Investing.com Nigeria
Indivior Q4 Earnings Call Highlights - Yahoo Finance
Indivior Q4 2025 slides: SUBLOCADE momentum drives earnings beat By Investing.com - Investing.com UK
Earnings call transcript: Indivior Q4 2025 beats expectations, stock rises By Investing.com - Investing.com UK
Indivior's Q4 Adjusted Earnings, Revenue Rise; Reaffirms 2026 Guidance - marketscreener.com
Indivior Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Full-Year 2026 - marketscreener.com
Earnings Flash (INDV) Indivior Pharmaceuticals, Inc. Reports Q4 Revenue $358.0M, vs. FactSet Est of $305.6M - marketscreener.com
Indivior Reports Record 2025 Results, Launches Share Buyback - TipRanks
Earnings Flash (INDV) Indivior Pharmaceuticals, Inc. Posts Q4 Adjusted EPS $0.82 per Share, vs. FactSet Est of $0.67 - marketscreener.com
Indivior Plc. Reports Increase In Q4 Bottom Line - Nasdaq
Indivior Pharmaceuticals : FINAL Indivior Corporate Investor Deck - marketscreener.com
Indivior Pharmaceuticals : FINAL Press Release - marketscreener.com
Indivior Pharmaceuticals : FINAL Indivior Q4 Financial Results Deck - marketscreener.com
Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results - The Manila Times
Indivior Returns to Havas With U.S. AOR Assignment - ADWEEK
Indivior Pharmaceuticals, Inc. (INDV) Investor Outlook: Strong Buy Ratings and 38% Upside Potential - DirectorsTalk Interviews
Indivior selects Havas U.S. integrated AOR - Medical Marketing and Media
Indivior to Participate in Upcoming Investor Conferences - The Manila Times
Indivior CEO lines up Miami investor talks and fireside chat - Stock Titan
Indivior PLC $INDV Shares Sold by Clark Estates Inc. NY - MarketBeat
Aberdeen Group plc Acquires New Position in Indivior PLC $INDV - MarketBeat
INDV SEC FilingsIndivior Pharmaceuticals Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) Presents a High-Growth Momentum and Technical Setup Case - ChartMill
Persistent Asset Partners Ltd Acquires Shares of 58,409 Indivior PLC $INDV - MarketBeat
Indivior Pharmaceuticals to Report Q4 Earnings: What's in the Cards? - The Globe and Mail
Principal Financial Group Inc. Invests $1.70 Million in Indivior PLC $INDV - MarketBeat
Fuller & Thaler discloses 5.10% Indivior (INDV) stake on Schedule 13G - Stock Titan
Indivior Pharmaceuticals, Inc. (INDV) Investor Outlook: Navigating a 34.59% Potential Upside - DirectorsTalk Interviews
VELA International Fund's Indivior Pharmaceuticals Inc(INDV) Holding History - GuruFocus
INDV PE Ratio & Valuation, Is INDV Overvalued - Intellectia AI
Analysts Offer Insights on Healthcare Companies: Indivior (INDV) and NeoGenomics (NEO) - The Globe and Mail
Goldman Sachs (INDV) discloses 2.9% beneficial stake in Indivior - Stock Titan
Indivior Pharmaceuticals Inc (INDV) 財務データ
収益
当期純利益
現金流量
EPS
1.37%
1.33%
大文字化:
|
ボリューム (24 時間):